2 news items
Longboard Pharmaceuticals Announces Interim Results From 52-Week Open-Label Extension Of PACIFIC Study Evaluating Bexicaserin (LP352) In Participants With Developmental And Epileptic Encephalopathies
LBPH
10 Jun 24
; participants randomized to the PACIFIC placebo group achieved a median seizure reduction of 57.3%Favorable safety and tolerability results
Longboard Pharmaceuticals Announces Positive Interim Results from the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Evaluating Bexicaserin in Participants with Developmental and Epileptic Encephalopathies (DEEs)
LBPH
10 Jun 24
%
Favorable safety and tolerability results observed
- Prev
- 1
- Next